ZVSA (ZyVersa Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


ZVSA ZyVersa Therapeutics Inc ZVSA
30 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is ZyVersa Therapeutics EBITDA Margin %?

ZyVersa Therapeutics ZVSA -9.60% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates ZVSA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, ZyVersa Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ZyVersa Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-1.66 Mil. ZyVersa Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, ZyVersa Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

ZyVersa Therapeutics  (OTCPK:ZVSA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

ZyVersa Therapeutics EBITDA Margin % Related Terms

ZyVersa Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for ZyVersa Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZyVersa Therapeutics EBITDA Margin % Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ZyVersa Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ZVSA vs CLSDQ, ADAPY, BPTH: EBITDA Margin % Comparison

For the Biotechnology subindustry, ZyVersa Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's EBITDA Margin % falls into.


ZVSA
30GF Score
ZyVersa Therapeutics Inc ZVSA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZyVersa Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ZyVersa Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-25.291/0
= %

ZyVersa Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.661/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
ZyVersa Therapeutics (ZVSA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ZyVersa Therapeutics and its competitors. According to the industry distribution chart, ZyVersa Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is ZyVersa Therapeutics' EBITDA Margin % too high?
ZyVersa Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, ZyVersa Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ZyVersa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ZyVersa Therapeutics' EBITDA Margin % compare to CLSDQ and ADAPY?
According to the Biotechnology industry distribution chart, ZyVersa Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places ZyVersa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ZyVersa Therapeutics and its competitors. ZyVersa Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZyVersa Therapeutics stock overvalued right now?
ZyVersa Therapeutics (ZVSA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. ZyVersa Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ZyVersa Therapeutics (ZVSA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZyVersa Therapeutics Business Description

Address 2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
30GF Score

Get the complete analysis for ZVSA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price